Total population (n = 307) | PALS > 15% (n = 127) | PALS ≤ 15% (n = 180) | P-value | |
---|---|---|---|---|
Echocardiographic data | ||||
LVEDV, mL | 169 (134–219) | 155 (127–209) | 180 (143–223) | 0.002 |
LVEDV index, mL/m2 | 93 (75–117) | 85 (71–106) | 98 (80–123) | 0.007 |
LVESV, mL | 110 (82–152) | 95 (75–134) | 125 (93–168) | < 0.001 |
LVESV index, mL/m2 | 62 (45–81) | 52 (41–70) | 69 (50–88) | < 0.001 |
LVEF, % | 35 (27–40) | 39 (32–43) | 31 (24–38) | < 0.001 |
LVEF < 30% | 104 (33.9) | 22 (17.3) | 82 (45–6) | < 0.001 |
LAVI, mL/m2 | 56 (43–72) | 45 (36–59) | 63 (50–77) | < 0.001 |
PALS, % | 14 (8–20) | 22 (18–26) | 9 (7–12) | < 0.001 |
EROA, mm2 | 15 (9–22) | 13 (7–18) | 16 (10–25) | 0.001 |
RegVol, mL | 25 (14–34) | 23 (12–33) | 25 (15–35) | 0.395 |
Severe MR | 32 (10.4) | 7 (5.5) | 25 (13.9) | 0.018 |
E, m/s | 0.87 (0.68–1.05) | 0.72 (0.57–0.94) | 0.94 (0.76–1.11) | < 0.001 |
E/E’ ratio | 13 (10–18) | 12 (9–15) | 15 (11–19) | < 0.001 |
TR ≥ moderate | 55 (17.9) | 7 (5.5) | 48 (26.7) | < 0.001 |
SPAP, mmHg | 41 (33–51) | 33 (29–42) | 47 (36–56) | < 0.001 |
TAPSE, mm | 19 (15–22) | 20 (18–22) | 17 (14–20) | < 0.001 |